Tarsus Pharmaceuticals Q2 2024 GAAP EPS $(0.88) Beats $(0.94) Estimate, Sales $40.813M Beat $31.664M Estimate
Tarsus Pharmaceuticals Q2 2024 GAAP EPS $(0.88) Beats $(0.94) Estimate, Sales $40.813M Beat $31.664M Estimate
tarsus pharmaceuticals 2024年第二季度GAAP每股收益为$(0.88)，高于$(0.94)的预估值；销售额为4081.3万美元，高于3166.4万美元的预估值。
Tarsus Pharmaceuticals (NASDAQ:TARS) reported quarterly losses of $(0.88) per share which beat the analyst consensus estimate of $(0.94) by 6.38 percent. This is a 24.79 percent increase over losses of $(1.17) per share from the same period last year. The company reported quarterly sales of $40.813 million which beat the analyst consensus estimate of $31.664 million by 28.89 percent.
tarsus pharmaceuticals（纳斯达克：TARS）报告本季度每股亏损0.88美元，超出分析师预期的0.94美元，增幅为6.38%。相比去年同期每股亏损1.17美元，增幅为24.79%。该公司报告本季度销售额为4081.3万美元，超出分析师预期的3166.4万美元，增幅为28.89%。